The Cancer Genome Characterization Initiative (CGCI)
The Cancer Genome Characterization Initiative (CGCI) supports the molecular characterization of tumors through the development and use of cutting-edge genomic approaches. Advancements in sequencing technologies in the late 1990s inspired a revolution in cancer research, which allowed for the comprehensive examination of cancer genomes at increasing levels of resolution. CGCI uses sequencing to identify novel genetic changes in various types of pediatric and adult cancers, including B-cell non-Hodgkin lymphoma, medulloblastoma, and HIV-associated cancers. Elucidating the genetic features of tumors contributes to a deeper understanding of their underlying molecular mechanisms and helps inform better diagnostic and therapeutic approaches.
CGCI remains at the forefront of cancer research by adopting and innovating newly emerging technologies and analytical tools. Improving sequence-based technologies accelerates discovery by increasing throughput, decreasing experimental costs, and enhancing the quality of data. Data collected from CGCI projects are made publicly available through databases supported by the National Institutes of Health (NIH) and National Cancer Institute (NCI) to facilitate and encourage other research endeavors.
- Non-Hodgkin Lymphoma
- HIV+ Tumor Molecular Characterization Project
- Lung Carcinogenesis
Learn about the various CGCI projects:
Access sequence data from the dbGaP CGCI study webpage and additional data from the Data Matrix on this website. dbGaP is supported by the National Center for Biotechnology Information, an NIH organization.
Read publications from CGCI projects.
Access protocols, templates, and policies.